|
This program is provisional and there will undoubtedly be additional speakers in the final version
|
Friday, September 5 |
| 07:15 - 07:45 |
Continental Breakfast |
|
| 07:50 - 08:00 |
Welcome |
J. Goldman
J. Cortes |
| 08:00 - 10:00 |
Session 1 - Activated kinases in leukemia - Chair: G. Daley (Boston) |
|
| Opening address: |
Targeting malignant stem cells |
P. Pandolfi (Boston) |
| Keynote: |
Title pending |
G. Gilliland (Boston) |
| |
JAK2 mutations and MPD pathogenesis |
T. Green (Cambridge, UK) |
| |
Molecular events involved in initiation and progression of MPDs |
C. Jamiesson (San Diego) |
| |
Acquired uniparental disomy and novel transforming mutations in atypical CML |
N. Cross (Southampton) |
| |
Tyrosine kinase inhibitors in eosinophilia-associated myeloproliferative disorders |
A. Reiter (Mannheim) |
| |
Discussion |
|
| 10:00 - 10:30 |
Break |
|
| 10:30 - 12:30 |
Session 2 - Molecular basis - chronic phase and progression - Chair: F. Frassoni |
|
| |
Analysis of signaling pathways and kinase inhibitors in CML stem/ myeloid progenitors |
R.van Etten (Boston) |
| |
Dissecting the role of GSK3b in CML stem/myeloid progenitors |
A.M. Coluccia (Lecce) |
| |
Genomic determinants of lineage and disease progression in BCR-ABL1 leukemia |
C. Mullighan (Memphis) |
| |
More on Ikaros in Ph-positive leukemias |
I. Iacobucci (Bologna) |
| |
Transcriptional control of ABL.BCR genes in CML: a clue to progression ? |
C. Gambacorti (Monza) |
| |
Deregulation of asymmetric division in the progression of chronic myelogenous leukemia |
H.Y. Kwon (Durham) |
| |
Mutagenesis to probe kinase regulation |
M. Azam (Boston) |
| |
Role of miR in CML |
M. Eder (Hannover) |
| |
Discussion |
|
| 12:00 - 13:00 |
Lunch |
|
| 13:00 - 15:30 |
Session 3 - Leukemia stem cells – identification and eradication - Chair: C. Eaves (Vancouver) |
|
| Keynote: |
Novel approaches to target cancer stem cells in CML |
T. Holyoake (Glasgow) |
| |
Targeting stem cells and progenitor CML cells by pharmacological restoration of PP2A tumor suppressor activity |
D. Perrotti (Columbus) |
| |
Properties of CD34+ CML cells that correlate with clinical response to tyrosine kinase inhibitors |
X. Jiang |
| |
Role of FoxO in the persistence of the leukemic progenitors in CML patients treated with TK inhibitors |
G. Saglio (Torino) |
| |
Do we need to kill the last CML cell? |
J. Melo (Adelaide) |
| |
Targeting of quiescent leukemia stem cells in chronic myelogenous leukemia by the histone
deacetylase inhibitor LAQ824 in combination with imatinib mesylate |
R. Bhatia (Los Angeles) |
| |
Functional insights of transcriptome analysis of CML stem cells |
Y. Zhao (Vancouver) |
| |
Eradication of the leukemia stem cell |
R. Sackstein (Boston) |
| |
Discussion |
|
| 16:00 - 16:30 |
Break |
|
| 16:30 - 18:30 |
Session 4 -
Leukemia stem cells – immune modulation - Chair: Barney Clarkson (New York) |
|
| Keynote: |
CTLs and vaccine strategies in CML |
K. Rezvani (London) |
| |
Control of the leukaemic stem cell by IFN producing plasmacytoid dendritic cell compartment |
F. Guilhot (Poitiers) |
| |
IFN-a activates quiescent HSCs in vivo |
M. Essers (Lausanne) |
| |
CML stem cells as targets for cellular and immunotherapy |
A. Yong (Bethesda) |
| |
Immunotherapy with gene modified T cells |
H. Stauss (London) |
| |
PRAME-specific CTLs and transgenic T cells to target CML |
F. Pane (Naples) |
| |
Novel chemical approaches to WT1 vaccines |
D. Scheinberg (New York) |
| |
Expansion of anti-leukemic/anti-host T/NK cells during dasatinib therapy |
K. Porkka (Helsinki) |
| |
Discussion |
|
| 20:00 |
Faculty Dinner:
Private Room, Sheraton Boston Hotel |
|
Saturday, September 6 |
| 07:30 – 08:00 |
Continental Breakfast |
|
| 08:00 - 09:00 |
Session 5 - Animal models of leukemia – what can we learn? - Chair: Alan Gewirtz |
|
| Keynote: |
Murine models of MPD as tools for assessing targeted therapy |
G. Gilliland (Boston) |
| |
Drosophila model to study BCR-ABL pathway |
D. Cilloni (Turin) |
| |
Inducible mouse models of leukemia |
S. Koschmieder (Munster |
| |
Molecular basis of HSC and myeloid progenitor compartment expansion induced by junB inactivation |
E. Passegue (San Francisco) |
| |
Discussion |
|
| 09:00 - 11:00 |
Session 6 -
Genomic instability - Chair: TBA |
|
Keynote: |
Mechanism of BCR/ABL-induced genomic instability causing resistance to small molecule inhibitors and malignant progression of CML |
T. Skorski (Philadelfia) |
| |
The B-cell lineage specific mutator AID (activation-induced cytidine deaminase) |
M. Muschen (Los Angeles) |
| |
Basis and effects of genomic instability |
M. Sattler (Boston) |
| |
“Back-up” non homologous end-joining (NHEJ) repair: Therapeutic targets in CML? |
F. Rassool (Baltimore) |
| |
Overcoming drug-resistance to tyrosine-kinase inhibitors in BCR-ABL1 driven leukemia |
G. Martinelli (Bologna) |
| |
Application of SNP-array technology to CML |
S. Soverini (Bologna) |
| |
Submicroscopic genomic lesions in CML at diagnosis |
A. Reid (London) |
| |
Inhibiting Abl compromises DNA repair in Bcr-Abl negative cells |
H. van der Kuip (Stuttgart) |
| |
Discussion |
|
| 11:00 - 11:30 |
Break |
|
| 11:30 - 13:00 |
Session 7 -
Targeting tyrosine kinases and signaling pathways - Chair: Nikolas von Bubnoff (Munich) |
|
| Keynote: |
Molecular characterization of the BCR-ABL molecular machine as the target of TKIs |
G. Superti-Furga (Vienna) |
| |
Global target profiles for CML TKIs |
O. Hantschel (Vienna) |
| |
Allosteric Bcr-Abl inhibitors: targeting the myristate binding site |
N. Gray (Boston) |
| |
Conformational dynamics in wildtype ABL, drug resistant mutants and inhibitor bound complexes |
John Engen (Boston) |
| |
Gene expression targets for diagnostics and therapy |
J. Radich (Seattle) |
| |
A novel small molecule disrupts the Bcr-Abl/Jak2/HSP90 network complex leading to apoptosis in blast crisis cells and T3 151 mutant cells |
R. Arlinghaus (Houston) |
| |
The combination of PHA - 739358 and imatinib is synergistic |
T. Brümmendorf (Hamburg) |
| |
Discussion |
|
| 13:30 - 14:30 |
Lunch |
|
| 13:30 - 15:30 |
Session 8 -
TKIs- how different are they in the clinic? - Chair: R. Stone (Boston) |
|
| Keynote: |
Outstanding issues with TKIs |
J. Cortes (Houston) |
| |
Imatinib |
J. Apperley (London) |
| |
Dasatinib - |
N. Shah (San Francisco) |
| |
Nilotinib |
G. Rosti (Bologna) |
| |
Bosutinib |
C. Gambacorti - Passerini (Monza) |
| |
Discussion |
|
| 16:00- 16:30 |
Break |
|
| 15:45 - 17:45 |
Session 9 -
Predicting and monitoring responses to imatinib - Chair: R. Silver (New York) |
|
| Keynote: |
Update on predictive assays for de-novo CML patients receiving TKI therapy |
T. Hughes (Adelaide) |
| |
Defining response TKIs and treatment recommendations |
M. Baccarani (Bologna) |
| |
The value of molecular monitoring for imatinib treated patients |
S. Branford (Adelaide) |
| |
Control of OCT1 expression |
L. Wang (Liverpool) |
| |
Is it possible to stop imatinib in CML patients? |
F.-X. Mahon (Bordeaux) |
| |
Interferon after stopping imatinib |
A. Carella (Genoa) |
| |
Discussion |
|
| 18.30 – 19.30 |
Poster Representations – (3 slides in 3 minutes) - Chairs: Rüdiger Hehlmann (Manheim) and Francisco cervantes (Barcelona) |
|
| Starting about 19.45 Ending about 22.30 |
Conference Gala Dinner – 50th Floor, Prudential Center
|
|
Sunday, September 7 |
| 07:30 - 08:00 |
Continental Breakfast |
|
| 08:00 - 10:00 |
Session 10 - Resistance to TKIs - Chair: C. Schiffer (Detroit) |
|
| Keynote: |
TKI resistance: mutations and more |
M. Deininger (Portland) |
| |
T3 151 mutated BCR-ABL expression in adult and ES cell derived hematopoiesis |
A. Turhan (Poitiers) |
| |
Dynamics of mutated clones in vivo |
A. Hochhaus (Mannheim) |
| |
T3 151 in chronic phase - an epidemiologic study |
F. Nicolini (Lyon) |
| |
Panale Discussion |
A. Turhan, M. Scherr, L. Foroni, P. Manley, T. Mughal |
| 10:00 - 10:30 |
Break |
|
| 10:30 - 12:30 |
Session 11 -
Challenges for the next decade - Chair: J. Cortes (Houston) |
|
| Keynote: |
Therapeutic thoughts for the future |
M. Talpaz (Ann Arbor) |
| |
What would it take to displace imatinib as first line treatment? |
C. Schiffer (Detroit) |
| |
Lessons from clinical trials |
S. O’Brien (Newscastle) |
| |
Panel Discussion |
J. Reiffers. P. Vale4nt. J. Cornelissen, A. Quintas Cardama |
| 12:30 - 12:45 |
Concluding Remarks |
J. Goldman (London)
|
| |
|
|
| |
Note: This program is still subject to minor changes. |
|
| |
|
|